Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

The only natural host of the hepatitis C virus (HCV) is humans. Model organisms for laboratory studies, especially mice, ...

A team of stem cell scientists have successfully used embryonic stem cell engineering to create a bi-paternal mouse—a mouse ...

In two new papers, researchers from The Jackson Laboratory (JAX) report the successful use of two approaches -- gene therapy ...

Scientists say identification of two epigenetically different states in mouse model opens door to "entirely new world of ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...

Researchers have successfully engineered bi-paternal mice, born from two male parents, that survived to adulthood using embryonic stem cell techniques.